Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.91B |
| 2 |
SPCX
SpaceX
SPCX
|
+$871M |
| 3 |
Eli Lilly
LLY
|
+$719M |
| 4 |
Amazon
AMZN
|
+$698M |
| 5 |
Netflix
NFLX
|
+$627M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$3B |
| 2 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$1.54B |
| 3 |
TSMC
TSM
|
+$1.42B |
| 4 |
NVIDIA
NVDA
|
+$1.41B |
| 5 |
SNDK
Sandisk
SNDK
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.67% |
| 2 | Technology | 3.92% |
| 3 | Healthcare | 2.55% |
| 4 | Industrials | 2.24% |
| 5 | Financials | 2.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NSRX
12801
Nasus Pharma
NSRX
$40.5M
| $77K | ﹤0.01% |
+22,004
| New | +$64.5K |
|
12802
Coya Therapeutics
COYA
$105M
| $76.7K | ﹤0.01% |
13,105
-3,754
| -22% | -$17.4K |
|
12803
CALL
Cardlytics
CDLX
$23.1M
| $76.4K | ﹤0.01% |
17,020
-6,260
| -27% | -$46.8K |
|
12804
CALL
Beam Global
BEEM
$30.6M
| $76.2K | ﹤0.01% |
58,600
+37,600
| +179% | +$57.7K |
|
12805
CALL
Cadiz
CDZI
$301M
| $76.1K | ﹤0.01% |
18,200
-16,900
| -48% | -$75.3K |
|
12806
Virco
VIRC
$97.3M
| $76K | ﹤0.01% |
+12,376
| New | +$75.1K |
|
12807
PUT
Orchestra BioMed
OBIO
$361M
| $75.9K | ﹤0.01% |
+17,600
| New | +$72K |
|
12808
PUT
Five Point Holdings
FPH
$365M
| $75.9K | ﹤0.01% |
14,400
+1,400
| +11% | +$7.02K |
|
|
ADIL
12809
Adial Pharmaceuticals
ADIL
$15.4M
| $75.6K | ﹤0.01% |
+29,547
| New | +$58.5K |
|
12810
CALL
Gerdau
GGB
$9.79B
| $75.5K | ﹤0.01% |
+18,700
| New | +$83.1K |
|
|
VNTG
12811
Vantage Corp
VNTG
$18.3M
| $75.5K | ﹤0.01% |
121,805
+111,129
| +1,041% | +$85K |
|
12812
Citius Pharmaceuticals
CTXR
$15.4M
| $75.5K | ﹤0.01% |
+124,910
| New | +$84.6K |
|
12813
ClearSign Technologies
CLIR
$24M
| $75.5K | ﹤0.01% |
+20,565
| New | +$97.4K |
|
12814
Sera Prognostics
SERA
$79.7M
| $75.4K | ﹤0.01% |
41,411
-207,498
| -83% | -$412K |
|
|
YI
12815
111 Inc
YI
$29.7M
| $75.3K | ﹤0.01% |
+17,339
| New | +$97.6K |
|
12816
CALL
Milestone Pharmaceuticals
MIST
$111M
| $75.2K | ﹤0.01% |
56,100
+19,800
| +55% | +$31.6K |
|
|
OGI
12817
Organigram Holdings
OGI
$153M
| $75K | ﹤0.01% |
73,575
+60,088
| +446% | +$73.4K |
|
12818
CALL
Health Catalyst
HCAT
$130M
| $75K | ﹤0.01% |
37,700
+25,200
| +202% | +$36.4K |
|
12819
Yatra Online
YTRA
$66.5M
| $75K | ﹤0.01% |
79,593
+68,829
| +639% | +$67K |
|
12820
CALL
ALX Oncology
ALXO
$243M
| $74.9K | ﹤0.01% |
36,200
-800
| -2% | -$1.43K |
|
12821
CALL
Pulmonx
LUNG
$83.7M
| $74.9K | ﹤0.01% |
+57,600
| New | +$79.3K |
|
12822
PUT
DMC Global
BOOM
$128M
| $74.4K | ﹤0.01% |
+12,800
| New | +$83.2K |
|
12823
CALL
Companhia Siderúrgica Nacional
SID
$1.6B
| $74.1K | ﹤0.01% |
+81,000
| New | +$101K |
|
12824
PUT
Priority Technology Holdings
PRTH
$486M
| $74K | ﹤0.01% |
11,100
-6,100
| -35% | -$35.3K |
|
12825
Scienjoy Holding
SJ
$29M
| $74K | ﹤0.01% |
94,876
+9,476
| +11% | +$10.5K |
|
Similar funds
Citadel Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Citadel Advisors held 15,445 positions worth $875B, up 41% from $618B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Citadel Advisors's Q2 2026 filing shows 2,573 new, 6,088 increased, 4,803 reduced and 1,873 closed positions. Its largest new stake was SpaceX: 5,129,884 shares worth $876M. The largest sale was Micron Technology, an estimated $3B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 79% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q2 2026 buy was SpaceX: 5,129,884 shares worth $876M.
- Citadel Advisors added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.91B increase.
- Citadel Advisors's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $3B.
- Citadel Advisors fully exited iShares 7-10 Year Treasury Bond ETF in Q2 2026, selling an estimated $325M.
- Citadel Advisors's ten largest holdings make up 23% of its $875B portfolio in Q2 2026.
- Citadel Advisors opened 2,573 new positions and closed 1,873 in Q2 2026.
- Citadel Advisors's portfolio value rose 41% quarter-over-quarter to $875B.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.